Collegium Appoints Vikram Karnani as Chief Executive Officer
Collegium Pharmaceutical (COLL) has appointed Vikram Karnani as President and CEO, effective November 12, 2024. Karnani brings over 15 years of life sciences leadership experience, notably from Horizon Therapeutics where he helped grow annual net product sales from $300 million to nearly $4 billion. He succeeds interim CEO Michael Heffernan, who will remain Board Chairman.
The appointment comes as Collegium's pain portfolio achieves record revenue, with Jornay PM positioned as the lead growth driver. Karnani most recently served as Executive VP and President of Global Commercial Operations and Medical Affairs (Rare Disease) at Amgen, following its acquisition of Horizon in 2023.
Collegium Pharmaceutical (COLL) ha nominato Vikram Karnani come Presidente e CEO, a partire dal 12 novembre 2024. Karnani porta con sé oltre 15 anni di esperienza nella leadership nelle scienze della vita, in particolare con Horizon Therapeutics, dove ha contribuito a far crescere le vendite nette annuali dei prodotti da 300 milioni a quasi 4 miliardi di dollari. Succede a Michael Heffernan, CEO ad interim, che rimarrà Presidente del Consiglio.
La nomina arriva mentre il portafoglio di prodotti contro il dolore di Collegium raggiunge un fatturato record, con Jornay PM posizionato come il principale motore di crescita. Karnani ha ricoperto più recentemente il ruolo di VP Esecutivo e Presidente delle Operazioni Commerciali Globali e Affari Medici (Malattie Rare) presso Amgen, dopo l'acquisizione di Horizon nel 2023.
Collegium Pharmaceutical (COLL) ha nombrado a Vikram Karnani como Presidente y CEO, a partir del 12 de noviembre de 2024. Karnani aporta más de 15 años de experiencia en liderazgo en ciencias de la vida, notablemente de Horizon Therapeutics, donde ayudó a aumentar las ventas anuales netas de productos de 300 millones a casi 4 mil millones de dólares. Sucede al CEO interino Michael Heffernan, quien permanecerá como Presidente de la Junta.
La designación se produce mientras el portafolio de productos para el dolor de Collegium alcanza ingresos récord, con Jornay PM posicionado como el principal motor de crecimiento. Karnani se desempeñó más recientemente como VP Ejecutivo y Presidente de Operaciones Comerciales Globales y Asuntos Médicos (Enfermedades Raras) en Amgen, tras la adquisición de Horizon en 2023.
Collegium Pharmaceutical (COLL)는 Vikram Karnani를 2024년 11월 12일부터 사장 겸 CEO로 임명했습니다. Karnani는 Horizon Therapeutics에서 연 매출을 3억 달러에서 거의 40억 달러로 성장시키는데 기여하며 15년 이상의 생명 과학 리더십 경험을 가지고 있습니다. 그는 임시 CEO인 Michael Heffernan의 뒤를 이어 취임하며, Heffernan은 이사회 의장을 계속 맡게 될 것입니다.
이번 임명은 Collegium의 통증 포트폴리오가 기록적인 수익을 달성함에 따라 이루어지며, Jornay PM이 주요 성장 동력으로 자리 잡고 있습니다. Karnani는 최근 Amgen에서 글로벌 상업 운영 및 의료 업무(희귀 질환) 부사장 겸 사장으로 재직했으며, 2023년에 Horizon을 인수한 이후부터입니다.
Collegium Pharmaceutical (COLL) a nommé Vikram Karnani en tant que Président et CEO, à partir du 12 novembre 2024. Karnani apporte plus de 15 ans d'expérience en leadership dans le domaine des sciences de la vie, notamment chez Horizon Therapeutics, où il a aidé à faire passer les ventes nettes annuelles de produits de 300 millions à près de 4 milliards de dollars. Il succède à Michael Heffernan, CEO intérimaire, qui restera Président du Conseil.
Cette nomination intervient alors que le portefeuille de produits anti-douleur de Collegium atteint des revenus records, avec Jornay PM positionné comme le principal moteur de croissance. Karnani a récemment occupé le poste de VP Exécutif et Président des Opérations Commerciales Globales et des Affaires Médicales (Maladies Rares) chez Amgen, suite à l'acquisition de Horizon en 2023.
Collegium Pharmaceutical (COLL) hat Vikram Karnani zum Präsidenten und CEO ernannt, mit Wirkung zum 12. November 2024. Karnani bringt über 15 Jahre Führungserfahrung im Bereich der Lebenswissenschaften mit, insbesondere von Horizon Therapeutics, wo er dazu beigetragen hat, die jährlichen Nettoumsätze von 300 Millionen auf fast 4 Milliarden Dollar zu steigern. Er tritt die Nachfolge des interimistischen CEOs Michael Heffernan an, der weiterhin Vorsitzender des Vorstandes bleibt.
Die Ernennung erfolgt, während das Schmerzportfolio von Collegium Rekordumsätze erzielt, wobei Jornay PM als Hauptwachstumstreiber positioniert ist. Karnani war zuletzt als Executive VP und Präsident für Globale Kommerzielle Operationen und Medizinische Angelegenheiten (Seltene Krankheiten) bei Amgen tätig, nach der Übernahme von Horizon im Jahr 2023.
- Record revenue performance from pain portfolio
- Appointment of experienced CEO with proven track record of growing revenue from $300M to $4B at previous company
- Strong positioning of Jornay PM as lead growth driver
- None.
Vikram Karnani is a Proven Industry Leader with Extensive Experience Growing Commercial Biopharmaceutical Businesses
STOUGHTON, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that Vikram Karnani has been appointed as President and Chief Executive Officer (CEO) of Collegium and will join its Board of Directors effective November 12, 2024. Michael Heffernan, who has served as Interim President and CEO since May 2024, will remain Chairman of the Board.
Mr. Karnani has more than 15 years of leadership experience in the life sciences industry. Over the course of nearly a decade at Horizon Therapeutics, Mr. Karnani held leadership positions spanning many aspects of the business, including leading Horizon’s growth strategy and its transformation into a leader in rare disease medicines as well as establishing and expanding Horizon’s presence in international markets. This culminated in his leadership of the integration of the Horizon rare disease business into Amgen following the acquisition in 2023. During his tenure, annual net product sales grew from approximately
“Vikram’s demonstrated success in building organizations and maximizing their potential through both organic growth and business development makes him the right fit to lead Collegium through its next phase of growth,” said Mr. Heffernan. “The outlook for Collegium has never been stronger. With our pain portfolio delivering record revenue and Jornay PM® poised to become our lead growth driver, we are well positioned, with Vikram as our new CEO, for continued success in 2025 and beyond.”
“Collegium is a leader in specialty pharmaceuticals with an impressive track record of commercial growth and capital deployment and has a talented team dedicated to improving the lives of people living with serious medical conditions,” said Mr. Karnani. “Collegium’s leadership in responsible pain management and recent expansion into neurology underscore the Company’s significant growth prospects and ability to generate value for shareholders. I am excited to join Collegium at this pivotal time and work with this accomplished team to lead the business as we build a leading, diversified specialty pharmaceutical company.”
Vikram Karnani most recently served as Executive Vice President and President, Global Commercial Operations and Medical Affairs (Rare Disease) at Amgen, where he was responsible for driving the global commercial strategy for Amgen’s portfolio of rare disease medicines. Prior to joining Amgen through its 2023 acquisition of Horizon, Mr. Karnani held numerous roles of increasing responsibility at Horizon that culminated in his position as Executive Vice President and President of Global Commercial and Medical Affairs, responsible for Horizon’s portfolio of rare disease medicines. Before joining Horizon in 2014, Mr. Karnani served as Vice President of the Therapeutics and Cell Therapy business and held leadership roles in strategy and business development at Fresenius Kabi. Mr. Karnani has a Master of Business Administration from Kellogg School of Management at Northwestern University, a Master of Science in Electrical Engineering from Case Western Reserve University and a Bachelor’s degree in Electrical Engineering from University of Mumbai in India.
About Collegium Pharmaceutical, Inc.
Collegium is a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company’s website at www.collegiumpharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Examples of forward-looking statements contained in this press release include, among others, statements related to our aspirations for the performance of our newly appointed executive and expectations relating to our future financial performance and growth. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results, performance, or achievements to differ materially from the company's current expectations, including risks relating to, among others: unknown liabilities; risks related to future opportunities and plans for our products, including uncertainty of the expected financial performance of such products; our ability to commercialize and grow sales of our products; our ability to successfully integrate the operations of Ironshore into our organization, and realize the anticipated benefits associated with the acquisition; our ability to manage our relationships with licensors; the success of competing products that are or become available; our ability to maintain regulatory approval of our products, and any related restrictions, limitations, and/or warnings in the label of our products; the size of the markets for our products, and our ability to service those markets; our ability to obtain reimbursement and third-party payor contracts for our products; the rate and degree of market acceptance of our products; the costs of commercialization activities, including marketing, sales and distribution; changing market conditions for our products; the outcome of any patent infringement or other litigation that may be brought by or against us; the outcome of any governmental investigation related to our business; our ability to secure adequate supplies of active pharmaceutical ingredient for each of our products and manufacture adequate supplies of commercially saleable inventory; our ability to obtain funding for our operations and business development; regulatory developments in the U.S.; our expectations regarding our ability to obtain and maintain sufficient intellectual property protection for our products; our ability to comply with stringent U.S. and foreign government regulation in the manufacture of pharmaceutical products, including U.S. Drug Enforcement Agency, or DEA, compliance; our customer concentration; and the accuracy of our estimates regarding expenses, revenue, capital requirements and need for additional financing. These and other risks are described under the heading "Risk Factors" in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q and other filings with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
Investor Contact:
Danielle Jesse
Director, Investor Relations
ir@collegiumpharma.com
Media Contact:
Marissa Samuels
Vice President, Corporate Communications
communications@collegiumpharma.com
FAQ
Who is the new CEO of Collegium Pharmaceutical (COLL)?
What is Vikram Karnani's previous experience before joining Collegium (COLL)?
What are Collegium's (COLL) current business performance highlights?